Copyright: ©Author(s) 2026.
World J Exp Med. Mar 20, 2026; 16(1): 117024
Published online Mar 20, 2026. doi: 10.5493/wjem.v16.i1.117024
Published online Mar 20, 2026. doi: 10.5493/wjem.v16.i1.117024
Table 2 Summary of endocrinology effect on very low-density lipoprotein
| Disorder/syndrome | Impact due to VLDL | Ref. |
| Cushing syndrome | Enhanced production | [61] |
| Exogenous cortisol | Decrease in degradation and enhanced adipose lipolysis | [62] |
| Aldosterone | Stimulation of aldosterone secretion | [65-67] |
| Growth hormone deficiency | Enhanced secretion and decline in clearance | [61] |
| Growth hormone treatment | Increased adipose lipolysis and increased clearance | [61] |
| Hypothyroidism | Decreased degradation with enhanced secretion | [73,74] |
| Androgen | Androgen-deprivation treatment: Enhanced concentration; transgender males with testosterone treatment: Enhanced concentration | [80-82] |
| Polycystic ovary syndrome | Enhanced concentration | [84] |
| Estrogen/progesterone therapy | Enhanced concentration | [85,86] |
| Prolactinoma | Uncertain | [94-96] |
- Citation: Bharadwaj A, Taneja M, Dubey S, Saxena A. Very low-density lipoprotein and the human health. World J Exp Med 2026; 16(1): 117024
- URL: https://www.wjgnet.com/2220-315x/full/v16/i1/117024.htm
- DOI: https://dx.doi.org/10.5493/wjem.v16.i1.117024